Novartis’ former CEO joining Amylin’s board and an appointment at OctoPlus – People on the move
Amylin Pharmaceuticals has appointed Paulo Costa as chairman of the board. Costa was formerly president and CEO of Novartis and before this he worked at Johnson & Johnson for 30 years.
John Doyle has been appointed chief operating officer of Achaogen. Doyle joins the company from Genentech and has previously held positions at Renovis and Tularik.
Adamas Pharmaceuticals has expanded its management team by making two appointments. Michael Coffee has joined the company as senior vice president (SVP), sales and marketing.
Coffee has more than 30 years experience in the pharma industry at companies including Avigen, Elan Pharmaceuticals, Bayer AG and Sandoz.
In addition Amy Patick has been appointed as VP, research. Patick has worked at Bristol-Myers Squibb, Agouron Pharmaceuticals and Genelabs Technologies in her 20 years in the industry.
GENova Biotherapeutics has appointed Aaron Whiteman as CEO. Whiteman has previously worked at Pfizer, Amgen, Medarex and Biogen Idec.
Mark Booth has joined Orexigen Therapeutics as chief commercial officer. Before joining Orexigen Booth worked at Takeda, Immunex and Abbott Laboratories.
OctoPlus’ chief scientific officer Joost Holthuis is leaving the company after working there for 15 years. Holthuis will continue to help OctoPlus on a consultancy basis.
Stephen DiPalma has resigned from his job as executive VP of business operations and chief financial officer at RXi Pharmaceuticals. DiPalma has left to pursue other opportunities.
John Schmidt is leaving his post as chief scientific officer at Alnylam Pharmaceuticals.
